Sotatercept

Phase 1Completed

1 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Healthy

Conditions

Healthy

Trial Timeline

Nov 22, 2023 → May 21, 2024

NCT ID

NCT06843460

About Sotatercept

Sotatercept is a phase 1 stage product being developed by Merck for Healthy. The current trial status is completed. This product is registered under clinical trial identifier NCT06843460. Target conditions include Healthy.

What happened to similar drugs?

20 of 20 similar drugs in Healthy were approved

Approved (20) Terminated (1) Active (0)

✅mRNA-1273.712ModernaApproved

✅Cholestyramine + Colesevelam HClDaiichi SankyoApproved

✅Cholestyramine + Cholestyramine + TangDaiichi SankyoApproved

✅Olmesartan medoxomil + Irbesartan + ValsartanDaiichi SankyoApproved

✅Perampanel 6 MGEisaiApproved

✅eszopiclone, zolpidem, placeboSumitomo PharmaApproved

✅Listerine Experimental Mouthwash + Colgate Cavity Protection Toothpaste + Listerine Total Care ZeroJohnson & JohnsonApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (12)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07140484	Approved	Recruiting	Oct 6, 2025	Jan 1, 2030	Pulmonary Artery Hypertension
NCT06658522	Approved	Recruiting	May 14, 2025	May 1, 2026	Pulmonary Arterial Hypertension PAH
NCT06814145	Phase 2	Recruiting	Apr 16, 2025	Mar 30, 2029	Hypertension, Pulmonary
NCT06843460	Phase 1	Completed	Nov 22, 2023	May 21, 2024	Healthy
NCT05818137	Phase 3	Completed	May 10, 2023	Nov 6, 2025	Pulmonary Arterial Hypertension
NCT05587712	Phase 2	Recruiting	Jan 19, 2023	Sep 21, 2028	Pulmonary Arterial Hypertension
NCT04811092	Phase 3	Completed	Mar 18, 2022	Apr 3, 2025	Pulmonary Arterial Hypertension
NCT04896008	Phase 3	Completed	Dec 1, 2021	Feb 18, 2025	Pulmonary Arterial Hypertension
NCT07218029	Phase 3	Recruiting	May 12, 2021	Dec 7, 2028	Pulmonary Arterial Hypertension
NCT03738150	Phase 2	Completed	Apr 19, 2019	Mar 22, 2022	Pulmonary Arterial Hypertension
NCT01736683	Phase 2	Completed	Nov 28, 2012	Apr 30, 2018	Anemia
NCT01190644	Phase 2	Terminated	Jun 1, 2010	Oct 29, 2012	Solid Tumors

Competing Products

20 competing products in Healthy

See all competitors

Product	Company	Stage	Hype Score
Use of Wearable Digital Sensors After mRNA Vaccination in Adults	Moderna	Preclinical	0
mRNA-0184	Moderna	Phase 1	0
mRNA-6231	Moderna	Phase 1	0
Letrozole	Dr. Reddy's Laboratories	Phase 1	26
Isotretinoin	Dr. Reddy's Laboratories	Phase 1	26
Fexofenadine	Dr. Reddy's Laboratories	Phase 1	26
Sertraline	Dr. Reddy's Laboratories	Phase 1	26
Nizatidine + Axid	Dr. Reddy's Laboratories	Phase 1	26
Anastrozole	Dr. Reddy's Laboratories	Phase 1	26
mRNA-1273.712	Moderna	Approved	0
Risperidone	Dr. Reddy's Laboratories	Phase 1	26
Lamotrigine	Dr. Reddy's Laboratories	Phase 1	26
Metformin + Glucophage	Dr. Reddy's Laboratories	Phase 1	26
Lamotrigine	Dr. Reddy's Laboratories	Phase 1	26
mRNA-0184	Moderna	Phase 1	0
Divalproex Sodium	Dr. Reddy's Laboratories	Phase 1	26
Sirolimus	Dr. Reddy's Laboratories	Phase 1	26
Glimepiride	Dr. Reddy's Laboratories	Phase 1	26
Ziprasidone Hydrochloride	Dr. Reddy's Laboratories	Phase 1	26
Naproxen sodium	Dr. Reddy's Laboratories	Phase 1	26